Substance use disorder treatment must become mainstream says former Obama Deputy Drug Czar
NZ Drug Foundation and NZ Society on Alcohol and Drug Dependence media release
30 August 2011: Embargoed until 9.30am
A visiting drug policy expert and one-time “Deputy Drug Czar” to the Obama Administration has told a symposium in
Wellington today that the historical approach to treating substance use disorders has missed the mark and has had
serious costs and consequences for healthcare in general.
Tom McLellan, Professor of Psychology in Psychiatry and Director of the Centre for Substance Abuse Solutions at the
University of Pennsylvania, said the substance abuse field has become segregated from the rest of medicine.
“Addiction is currently the only illness for which we have specialty care, but no meaningful involvement from primary
care professionals such as GPs. That means there is little available to treat those with substance use disorders before
they get to the stage where we deem them addicts.”
Professor McLellan said there is a difference between addiction and a substance use disorder.
“Imagine if, in the treatment of diabetes, we didn’t decide someone needed treatment until they got to the stage where
they lost their toes or their eyesight.
“If we took that approach we’d put little time or effort into diabetes prevention or early intervention, and we wouldn’t
bother teaching about its early symptoms in medical schools. That’s exactly what’s happening with substance use
disorders right now.
“The result is addicts are marginalised, stigmatised and pushed to the outer edges of society, much as sufferers from
TB, polio, breast cancer and depression once were – with generally poor outcomes and significant social costs.
“When substance use problems are involved, even at a low level, diagnosis, treatment and management of conditions become
complicated because of the lack of knowledge and training among those in the general medical field. This seriously
impairs the ability of mainstream healthcare to treat most chronic illnesses effectively and economically.”
Professor McLellan says America’s healthcare reforms and the Parity Act have paved the way for better integration of
substance use disorder care into mainstream healthcare.
“There will be many bumps along the road but I foresee big improvements in the decade.
“I don’t want to presume too much from the American experience but if there is similar segregation of prevention and
treatment of substance use disorders from the rest of mainstream healthcare in New Zealand, I think you may have many of
the same problems and the same unnecessary costs.”
Professor McLellan was one of nine keynote speakers at the Through the Maze: Making treatment better Drug Policy
Symposium organised by the New Zealand Drug Foundation and New Zealand Society on Alcohol and Drug Dependence.
The purpose of the invitation only symposium was to help focus the attention of policy makers and funders on ways to
develop a high quality addiction treatment system that gets more people into treatment and retains those who are already
in.
The Symposium’s organisers believe this is a challenging time for addiction treatment services in New Zealand. Alcohol
and other drug abuse is the sixth highest contributor to New Zealand’s burden of disease. Yet successive governments
have underinvested in addiction treatment services that are proven to reduce alcohol and other drug harm.
ENDS